Sanofi S.A., FR0000120578

Sanofi stock: JP Morgan keeps EUR 85.00 target for Sanofi stock

Published on 10/22/2026 at 17:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi reports third-quarter results October 30, 2026. Sanofi stock costs EUR 74.55 on October 22, 2026, up 1.33 percent versus the Xetra close.

Analyst target and reporting date

JP Morgan kept its Neutral rating and EUR 85.00 target for Sanofi on October 21, 2026.
Sanofi will present third-quarter 2026 results on October 30, 2026.
Sanofi stock costs EUR 74.55 at Lang & Schwarz on October 22, 2026 at 5:04 p.m. CEST, 1.33 percent above the Xetra close of October 21, 2026.
The stock's 52-week range is EUR 69.75 to EUR 91.15, while its year-to-date performance is minus 11.06 percent.

Editorial photograph of financial trading monitors displaying pharmaceutical sector index charts and CAC 40 and EURONEXT tickers in a dark trading room with blue screen glow — Sanofi FR0000120578 editorial trading room screens showing pharma sector index and CAC 40 charts, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) remains under a Neutral rating from JP Morgan, which kept its EUR 85.00 target on October 21, 2026, according to MarketScreener. The target lies 14.02 percent above the EUR 74.55 price. At Lang & Schwarz, Sanofi was trading at EUR 74.55 on October 22, 2026 at 5:04 p.m. CEST, up 1.33 percent versus the Xetra close of October 21, 2026 at EUR 73.57.

RBC target is EUR 75.00

RBC Capital had lowered its target from EUR 80.00 to EUR 75.00 on October 16, 2026 while keeping a Sector Perform rating, MarketScreener reported. The revised target is 0.60 percent above the Lang & Schwarz price, leaving the two recent analyst views close to the current euro quotation.

EUR 69.75 low still matters

Sanofi's 52-week range was EUR 69.75 to EUR 91.15 on October 21, 2026. The Lang & Schwarz price stood 6.88 percent above the low and 18.21 percent below the high. The stock's year-to-date performance was minus 11.06 percent, while the October 21 Euronext Paris volume reached 1,313,585 shares.

October 30 results set the next date

Sanofi will review its third-quarter 2026 results on October 30, 2026, with management presenting the figures and answering questions from the financial community, according to the company's Investor Relations page. The calendar also lists a January 28, 2027 presentation for fourth-quarter and full-year 2026 results. The October date is the nearer scheduled event for the stock.

Comparison with peers

Sanofi: up 1.33 percent versus the Xetra close, P/E 11.70, dividend yield 5.80 percent, on October 22, 2026. GSK: up 2.28 percent, P/E 16.01, on October 22, 2026 in GBp. Pfizer: up 1.57 percent, P/E 40.06, on October 22, 2026 in USD.

What matters for Sanofi stock

For investors, the gap between the EUR 85.00 JP Morgan target and the current euro price is smaller than the distance to the 52-week high. The October 30 results therefore provide the next scheduled test for the valuation and for the market's view of the pipeline.

Sanofi stock was trading at EUR 74.55 at Lang & Schwarz on October 22, 2026 at 5:04 p.m. CEST, 1.33 percent above the Xetra close of October 21, 2026 at EUR 73.57. The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.